View Cart  

FDA Reclassifies Clinical Hold on Repros’ Mid-Stage Endometriosis Trial

A A
The FDA reclassified its clinical hold on Repros Therapeutics’ Proellex and will now allow the company to conduct a Phase II trial of low-dose Proellex as a treatment for endometriosis.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00